Supernus Announces Second Quarter 2022 Financial Results
04 août 2022 16h01 HE
|
Supernus Pharmaceuticals, Inc.
Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating...
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
25 juil. 2022 17h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the Jefferies Healthcare Conference
02 juin 2022 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2022 Financial Results
09 mai 2022 16h05 HE
|
Supernus Pharmaceuticals, Inc.
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43,...
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
02 mai 2022 16h55 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
29 avr. 2022 20h00 HE
|
Supernus Pharmaceuticals, Inc.
First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,...
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
13 avr. 2022 16h11 HE
|
Supernus Pharmaceuticals, Inc.
Annual Report on Form 10-K filed on April 13, 2022Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE...
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
04 avr. 2022 17h00 HE
|
Supernus Pharmaceuticals, Inc.
Annual Report on Form 10-K for fiscal year ended December 31, 2021 to be filed in the near termReiterates full year 2022 financial guidance provided on February 28, 2022 ROCKVILLE, Md., April 04,...
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
17 mars 2022 08h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Annual Cowen Health Care Conference
02 mars 2022 08h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...